罗欣药业集团股份有限公司关于持股5%以上股东及其一致行动人权益变动触及1%整数倍的公告

Group 1 - The core point of the announcement is that Luoxin Pharmaceutical Group Co., Ltd. disclosed changes in the equity of its major shareholders, specifically a reduction in shareholding by over 1% [2][4][21] - The major shareholder Fang Xiubao and its concerted actors, including Fang Donghui and Wenzhou Daren Enterprise Management Co., Ltd., have reduced their holdings by 1,595,800 shares, representing 0.15% of the total share capital [2][4] - Following this reduction, the combined shareholding of Fang Xiubao and its concerted actors decreased from 12.10% to 11.96% [2][4] Group 2 - The company held its 27th meeting of the fifth board of directors on August 1, 2025, to discuss various matters, including providing guarantees for its subsidiary [5][6] - The board approved a proposal to provide a guarantee of RMB 20 million for its subsidiary, Luoxin Anruo Weita Pharmaceutical (Chengdu) Co., Ltd., to support its operational needs [6][28] - The guarantee proposal will be submitted to the shareholders' meeting for approval, requiring a two-thirds majority vote [8][18] Group 3 - The company announced the convening of the 2025 Fourth Extraordinary General Meeting of Shareholders on August 18, 2025, to discuss the approved proposals from the board meeting [9][32] - The meeting will be held both in-person and via online voting, allowing shareholders to participate remotely [34][39] - The registration date for shareholders to attend the meeting is set for August 11, 2025 [35][36]